You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Eplontersen sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for eplontersen sodium and what is the scope of freedom to operate?

Eplontersen sodium is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eplontersen sodium has two hundred and twenty-nine patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for eplontersen sodium
International Patents:229
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:eplontersen sodium at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for eplontersen sodium
Generic Entry Date for eplontersen sodium*:
Constraining patent/regulatory exclusivity:
TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for eplontersen sodium

US Patents and Regulatory Information for eplontersen sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Astrazeneca Ab WAINUA (AUTOINJECTOR) eplontersen sodium SOLUTION;SUBCUTANEOUS 217388-001 Dec 21, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for eplontersen sodium

Country Patent Number Title Estimated Expiration
Hong Kong 1221485 用於調節 表達的組合物和方法 (COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION HBV TTR) ⤷  Sign Up
Russian Federation 2697152 СОПРЯЖЕННЫЕ АНТИСМЫСЛОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ (CONJUGATED ANTISENSE COMPOUNDS AND USE THEREOF) ⤷  Sign Up
Japan 6995478 ⤷  Sign Up
Australia 2022202770 COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION ⤷  Sign Up
Russian Federation 2015151199 СОПРЯЖЕННЫЕ АНТИСМЫСЛОВЫЕ СОЕДИНЕНИЯ И ИХ ПРИМЕНЕНИЕ ⤷  Sign Up
Israel 242124 תכשירים ושיטות למודולציה של ביטוי apolipoprotein c-iii (Compositions and methods for modulating apolipoprotein c-iii expression) ⤷  Sign Up
Costa Rica 20190269 COMPOSICIONES Y MÉTODOS PARA MODULAR LA EXPRESIÓN DE TTR Y VHB (Divisonal 2015-0612) (COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.